paroxetine has been researched along with ketamine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aronstam, RS; Introna, RP; Martin, DC | 1 |
| Ho, RC; Zhang, MW | 1 |
| Bracke, F; Frieling, H; Leffler, A | 1 |
1 review(s) available for paroxetine and ketamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for paroxetine and ketamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Inhibition of neuronal 5-HT uptake by ketamine, but not halothane, involves disruption of substrate recognition by the transporter.
Topics: Anesthetics; Animals; Brain; Halothane; Ketamine; Male; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin; Synaptosomes | 1990 |
The paroxetine controversy: lessons for ketamine trials.
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Humans; Ketamine; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2015 |
Antidepressants Are Poor Inhibitors of Heat-Evoked Ion Currents Mediated by TRPM2.
Topics: Adenosine Diphosphate Ribose; Amitriptyline; Animals; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Fluoxetine; HEK293 Cells; Hot Temperature; Humans; Ketamine; Lidocaine; Mice; Paroxetine; Pregabalin; Sertraline; TRPM Cation Channels | 2022 |